ClinicalTrials.gg
CompletedNCT02172950Updated Oct 27, 2021Results posted

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

A Phase 3 interventional study of rVIII-SingleChain in Hemophilia A and Severe Hemophilia A, sponsored by CSL Behring. Completed at 64 sites in 25 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Non-randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.

Enrollment
Largest of 11
246 · median 62
Started
2014
with 1 other
Phase 3
6 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Hemophilia A by CSL Limited, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 9th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hemophilia A by CSL Limited as a file.
02

Study summary

This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and previous exposure to FVIII products who achieve at least 100 exposure days (EDs) to rVIII-SingleChain in this study, as well as in previously untreated patients (PUPs) with no previous exposure to any FVIII product who achieve at least 50 EDs to rVIII-SingleChain in this study. A substudy (open to both PTPs and PUPs) will investigate the use of rVIII-SingleChain in surgery. A substudy (open to PUPs who develop an inhibitor to rVIII-SingleChain) will investigate the use of rVIII-SingleChain in immune tolerance induction (ITI) therapy.

03

Conditions studied

  • Hemophilia A
  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PTPs:

  • Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%) and who participated in a previous CSL-sponsored clinical study with rVIII-SingleChain.
  • Males 0 to \<65 years age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%), who have at least 50 EDs to any FVIII product, and who are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain.

PUPs:

  • Males 0 to \<18 years of who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%)
  • No prior exposure to any Factor VIII product (with the exception of short-term use of blood products).

ITI substudy:

  • PUPs who have developed a confirmed inhibitor to rVIII-SingleChain in the main study.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to rVIII-SingleChain or to any of rVIII-SingleChain or Chinese hamster ovary (CHO) proteins.
  • Currently receiving a therapy not permitted during the study.
  • Serum creatinine > 2 x , or aspartate aminotransferase > 5 x upper limit of normal at Screening (if specified)
  • Any first-order family (eg, siblings) history of FVIII inhibitors
  • For PTPs not rolling over directly from a CSL-sponsored clinical study with rVIII-SingleChain: any history of or current FVIII inhibitors
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Previously treated patients (PTPs)

    The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.

    Biological: rVIII-SingleChain

  • Experimental
    Previously untreated patients (PUPs)

    The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.

    Biological: rVIII-SingleChain

Interventions

  • Recombinant single-chain coagulation factor VIII

    Also known as: CSL627

06

What researchers measure

Primary outcomes

  1. Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627

    Time frame: At the closest visit after 100 EDs (up to 5 years).

  2. Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627

    High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.

    Time frame: At the closest visit after 50 EDs (up to 5 years).

  3. Percent Treatment Success for Major Bleeding Episodes in PUPs

    Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.

    Time frame: Up to 5 years

  4. Annualized Spontaneous Bleeding Rate in PUPs

    The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.

    Time frame: Up to 5 years

Secondary outcomes

  1. Percentage of Bleeding Episodes Treated Successfully in PTPs

    Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response".

    Time frame: Up to 5 years

  2. Annualized Bleeding Rate in PTPs and PUPs

    The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens

    Time frame: Up to 5 years

  3. Percentage of Bleeding Episodes Requiring 1, 2, 3, or > 3 Injections of CSL627 to Achieve Hemostasis in PTPs and PUPs

    Time frame: Up to 5 years

  4. Mean Number of On-demand Infusions of CSL627

    Time frame: Up to 5 years

  5. Mean On-demand Dose Administered of CSL627

    Time frame: Up to 5 years

  6. Mean Prophylaxis Dose Administered of CSL627

    Time frame: Up to 5 years

  7. Mean Total Amount of CSL627 Administered During Surgery Period in PTPs

    Time frame: Day of surgery up to 336 hours post-surgery

  8. Total Amount of CSL627 Administered During Surgery Period in PUPs

    Time frame: Day of surgery up to 336 hours post-surgery

  9. Hemostatic Efficacy of rVIII-SingleChain for PTPs and PUPs Who Undergo Surgery

    The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or poor/no response".

    Time frame: From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)

  10. Incidence of Inhibitor Formation to FVIII in PTPs After 10 EDs and After 50 EDs

    Time frame: Up to 5 years

  11. Percentage of PTPs and PUPs Developing Antibodies Against CSL627

    Time frame: PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).

  12. Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins

    Time frame: PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).

  13. Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627

    High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.

    Time frame: At the closest visit after 10 EDs (up to 5 years)

  14. Number of PUPs With Low-titer Inhibitor Formation to FVIII After 10 EDs and After 50 EDs With CSL627

    Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.

    Time frame: At the closest visit after 10 and after 50 EDs (up to 5 years)

  15. Incidence of Total Inhibitor Formation to FVIII in PUPs

    Time frame: Up to 5 years

  16. Percent Treatment Success for Non-major Bleeding Episodes in PUPs

    Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.

    Time frame: Up to 5 years

  17. Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627

    Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.

    Time frame: Up to 6 hours after first infusion

  18. Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values

    Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.

    Time frame: Up to 5 years

07

Results

Posted Oct 27, 2021

Participant flow

Participant flow — Overall Study
MilestonePreviously Treated Patients (PTPs)Previously Untreated Patients (PUPs)
Started22224
Completed19719
Not completed255
Withdrew: Physician decision33
Withdrew: Lack of efficacy10
Withdrew: Adverse event41
Withdrew: Withdrawal by subject100
Withdrew: Protocol violation10
Withdrew: Lost to follow-up10
Withdrew: Death10
Withdrew: Patient traveling10
Withdrew: Patient went to other country10
Withdrew: Patient relocated overseas11
Withdrew: Patient moving10

Outcome measures

PrimaryIncidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627
Time frame:
At the closest visit after 100 EDs (up to 5 years).
Reported as:
Number · percentage of paticipants
Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627
percentage of paticipantsCSL627: Previously Treated Patients (PTPs)
Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL6270
PrimaryNumber of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627

High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.

Time frame:
At the closest visit after 50 EDs (up to 5 years).
Reported as:
Number · participants
Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627
participantsCSL627: Previously Untreated Patients (PUPs)
Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL6275
PrimaryPercent Treatment Success for Major Bleeding Episodes in PUPs

Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.

Time frame:
Up to 5 years
Reported as:
Number · percentage of treatment success
Percent Treatment Success for Major Bleeding Episodes in PUPs
percentage of treatment successCSL627: Previously Untreated Patients (PUPs)
Percent Treatment Success for Major Bleeding Episodes in PUPs100
PrimaryAnnualized Spontaneous Bleeding Rate in PUPs

The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.

Time frame:
Up to 5 years
Reported as:
Mean · Number of Spontaneous bleeds per year
Annualized Spontaneous Bleeding Rate in PUPs
Number of Spontaneous bleeds per yearCSL627: Previously Untreated Patients (PUPs)
On-demand1.9 ± 2.252
Prophylaxis4.04 ± 6.374
SecondaryPercentage of Bleeding Episodes Treated Successfully in PTPs

Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response".

Time frame:
Up to 5 years
Reported as:
Number · Percentage of treated bleeding events
Percentage of Bleeding Episodes Treated Successfully in PTPs
Percentage of treated bleeding eventsCSL627: Previously Treated Patients (PTPs)
Percentage of Bleeding Episodes Treated Successfully in PTPs87.1 (75.3 to 93.7)
SecondaryAnnualized Bleeding Rate in PTPs and PUPs

The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens

Time frame:
Up to 5 years
Reported as:
Mean · Number of bleeds per year
Annualized Bleeding Rate in PTPs and PUPs
Number of bleeds per yearCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
On-demand28.32 ± 29.0145.12 ± 5.331
Prophylaxis2.84 ± 4.9815.94 ± 7.705
SecondaryPercentage of Bleeding Episodes Requiring 1, 2, 3, or > 3 Injections of CSL627 to Achieve Hemostasis in PTPs and PUPs
Time frame:
Up to 5 years
Reported as:
Number · Percentage of treated bleeds
Percentage of Bleeding Episodes Requiring 1, 2, 3, or > 3 Injections of CSL627 to Achieve Hemostasis in PTPs and PUPs
Percentage of treated bleedsCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
1 infusion71.577.5
2 infusions14.811.4
3 infusions6.95.4
>3 infusions6.33.5
SecondaryMean Number of On-demand Infusions of CSL627
Time frame:
Up to 5 years
Reported as:
Mean · Number of infusions
Mean Number of On-demand Infusions of CSL627
Number of infusionsCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
per participant per month6.26 ± 4.7781.23 ± 1.296
per participant per year75.18 ± 57.33514.75 ± 15.547
SecondaryMean On-demand Dose Administered of CSL627
Time frame:
Up to 5 years
Reported as:
Mean · IU/kg
Mean On-demand Dose Administered of CSL627
IU/kgCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
per participant per month210.39 ± 188.10641.93 ± 44.643
per participant per year2524.69 ± 2257.278503.16 ± 535.712
SecondaryMean Prophylaxis Dose Administered of CSL627
Time frame:
Up to 5 years
Reported as:
Mean · IU/kg
Mean Prophylaxis Dose Administered of CSL627
IU/kgCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
per participant per month380.95 ± 130.079389.30 ± 243.191
per participant per year4571.35 ± 1560.9444671.54 ± 2918.288
SecondaryMean Total Amount of CSL627 Administered During Surgery Period in PTPs
Time frame:
Day of surgery up to 336 hours post-surgery
Reported as:
Mean · IU
Mean Total Amount of CSL627 Administered During Surgery Period in PTPs
IUCSL627: Previously Treated Patients (PTPs)
Mean Total Amount of CSL627 Administered During Surgery Period in PTPs51663.0 ± 62033.25
SecondaryTotal Amount of CSL627 Administered During Surgery Period in PUPs
Time frame:
Day of surgery up to 336 hours post-surgery
Reported as:
Number · IU
Total Amount of CSL627 Administered During Surgery Period in PUPs
IUCSL627: Previously Untreated Patients (PUPs)
Participant 115693
Participant 25631
Participant 37330
SecondaryHemostatic Efficacy of rVIII-SingleChain for PTPs and PUPs Who Undergo Surgery

The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of "excellent, good, moderate or poor/no response".

Time frame:
From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)
Reported as:
Number · Number of surgeries
Hemostatic Efficacy of rVIII-SingleChain for PTPs and PUPs Who Undergo Surgery
Number of surgeriesCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
Excellent283
Good40
Moderate00
Poor/No response00
SecondaryIncidence of Inhibitor Formation to FVIII in PTPs After 10 EDs and After 50 EDs
Time frame:
Up to 5 years
Reported as:
Number · percentage of participants
Incidence of Inhibitor Formation to FVIII in PTPs After 10 EDs and After 50 EDs
percentage of participantsCSL627: Previously Treated Patients (PTPs)
after 10 EDs0
after 50 EDs0
SecondaryPercentage of PTPs and PUPs Developing Antibodies Against CSL627
Time frame:
PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).
Reported as:
Number · percentage of participants
Percentage of PTPs and PUPs Developing Antibodies Against CSL627
percentage of participantsCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
Percentage of PTPs and PUPs Developing Antibodies Against CSL62715.370.8
SecondaryPercentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins
Time frame:
PTPs: At the closest visit after 100 EDs (up to 5 years). PUPs: At the closest visit after 50 EDs (up to 5 years).
Reported as:
Number · percentage of participants
Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins
percentage of participantsCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins00
SecondaryNumber of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627

High-titer inhibitor is defined as an inhibitor titer of ≥ 5 Bethesda units/mL.

Time frame:
At the closest visit after 10 EDs (up to 5 years)
Reported as:
Number · participants
Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627
participantsCSL627: Previously Untreated Patients (PUPs)
Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL6274
SecondaryNumber of PUPs With Low-titer Inhibitor Formation to FVIII After 10 EDs and After 50 EDs With CSL627

Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.

Time frame:
At the closest visit after 10 and after 50 EDs (up to 5 years)
Reported as:
Number · participants
Number of PUPs With Low-titer Inhibitor Formation to FVIII After 10 EDs and After 50 EDs With CSL627
participantsCSL627: Previously Untreated Patients (PUPs)
after 10 EDs4
after 50 EDs0
SecondaryIncidence of Total Inhibitor Formation to FVIII in PUPs
Time frame:
Up to 5 years
Reported as:
Number · percentage of participants
Incidence of Total Inhibitor Formation to FVIII in PUPs
percentage of participantsCSL627: Previously Untreated Patients (PUPs)
Incidence of Total Inhibitor Formation to FVIII in PUPs50.0
SecondaryPercent Treatment Success for Non-major Bleeding Episodes in PUPs

Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of "excellent" or "good" on the investigator's clinical assessment of hemostatic efficacy 4-point scale "excellent, good, moderate or poor/no response". Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.

Time frame:
Up to 5 years
Reported as:
Number · percentage of treated bleeding events
Percent Treatment Success for Non-major Bleeding Episodes in PUPs
percentage of treated bleeding eventsCSL627: Previously Untreated Patients (PUPs)
Percent Treatment Success for Non-major Bleeding Episodes in PUPs92.1 (87.0 to 95.3)
SecondaryPercentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627

Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.

Time frame:
Up to 6 hours after first infusion
Reported as:
Number · percentage of participants
Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627
percentage of participantsCSL627: Previously Untreated Patients (PUPs)
Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL6270
SecondaryPercentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values

Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.

Time frame:
Up to 5 years
Reported as:
Number · percentage of participants
Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values
percentage of participantsCSL627: Previously Untreated Patients (PUPs)
Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values0

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CSL627: Previously Treated Patients (PTPs)1/222 (0.5%)23/222 (10.4%)130/222 (58.6%)
CSL627: Previously Untreated Patients (PUPs)0/24 (0%)14/24 (58.3%)23/24 (95.8%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
Anti factor VIII antibody positiveInvestigations0/2226/24
Inhibiting antibodies positiveInvestigations0/2225/24
FallInjury, poisoning and procedural complications0/2222/24
HaemorrhageVascular disorders0/2221/24
Wound haemorrhageInjury, poisoning and procedural complications0/2221/24
Factor VIII inhibitionBlood and lymphatic system disorders0/2221/24
Mouth haemorrhageGastrointestinal disorders0/2221/24
Muscle spasmsMusculoskeletal and connective tissue disorders0/2221/24
Device related infectionInfections and infestations0/2221/24
Acinetobacter infectionInfections and infestations0/2221/24
Most frequent other events
Showing 10 of 36
Most frequent other events
EventCSL627: Previously Treated Patients (PTPs)CSL627: Previously Untreated Patients (PUPs)
PyrexiaGeneral disorders14/22215/24
NasopharyngitisInfections and infestations40/2229/24
Upper respiratory tract infectionInfections and infestations25/2227/24
CoughRespiratory, thoracic and mediastinal disorders13/2226/24
RhinitisInfections and infestations7/2226/24
VaricellaInfections and infestations2/2226/24
DiarrhoeaGastrointestinal disorders5/2225/24
TonsillitisInfections and infestations13/2225/24
Ear infectionInfections and infestations5/2225/24
InfluenzaInfections and infestations14/2224/24

Baseline characteristics

Age was analyzed separately as PTPs and PUPs

Age, Categorical
Age, Categorical(Participants)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
<=18 years9524119
Between 18 and 65 years1260126
>=65 years101
Age, Continuous
Age, Continuous(years)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
PTPs22.5 ± 14.55—22.5 ± 14.55
PUPs—1.4 ± 1.181.4 ± 1.18
Sex: Female, Male
Sex: Female, Male(Participants)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
Female000
Male22224246
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
Hispanic or Latino10111
Not Hispanic or Latino21223235
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
American Indian or Alaska Native000
Asian50252
Native Hawaiian or Other Pacific Islander000
Black or African American12719
White15815173
More than one race000
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Previously Treated Patients (PTPs)Previously Untreated Patients (PUPs)Total
Czechia202
United States21122
Malaysia13215
Thailand10010
Portugal235
Austria606
Netherlands9312
Ireland505
Poland36036
France707
Romania404
Hungary202
Japan707
Philippines18018
Ukraine17017
United Kingdom101
Switzerland101
Spain606
Lebanon9312
Canada101
Italy549
South Africa14822
Georgia505
Australia11011
Germany10010
08

Study locations

64 sites
  • Study Site 8400213
    San Diego, California 92103-8651, United States
  • Study Site 8400241
    Aurora, Colorado 80045, United States
  • Study Site 8400118
    Hartford, Connecticut 06106, United States
  • Study Site 8400116
    Miami, Florida 33136, United States
  • Study Site 8400184
    Chicago, Illinois 60612, United States
  • Study Site 8400204
    New Orleans, Louisiana 70112, United States
  • Study Site 8400240
    Dallas, Texas 75390-9016, United States
  • Study Site 8400041
    Houston, Texas 77030, United States
  • Study Site 8400154
    Milwaukee, Wisconsin 53226, United States
  • Study Site 0360014
    Melbourne, 3052, Australia
  • Study Site 0360028
    Nedlands, WA 6009, Australia
  • Study Site 0360031
    Perth, WA 6000, Australia
  • Study Site 0400012
    Graz, 8036, Austria
  • Study Site 0400003
    Linz, 4020, Austria
  • Study Site 0400001
    Wien, 1090, Austria
  • Study Site 0400002
    Wien, 1090, Austria
  • Study Site 1240022
    Saint John, E2L 4L2, Canada
  • Study Site 2030017
    Hradec Kralove, 500 05, Czechia
  • Study Site 2500015
    Brest, 29609, France
  • Study Site 2500017
    Le Kremlin Bicetre, 94270, France
  • Study Site 2500028
    Lille Cedex, 59037, France
  • Study Site 2500018
    Nantes, 44093, France
  • Study Site 2500002
    Paris, 75015, France
  • Study Site 2680001
    Tbilisi, 0179, Georgia
  • Study Site 2760034
    Bonn, 53127, Germany
  • Study Site 2760091
    Frankfurt, 60596, Germany
  • Study Site 2760087
    Giessen, 35385, Germany
  • Study Site 2760066
    Hannover, 30625, Germany
  • Study Site 3480007
    Debrecen, 4032, Hungary
  • Study Site 3720002
    Dublin, 12, Ireland
  • Study Site 3800023
    Milano, 20122, Italy
  • Study Site 3920031
    Hyogo, 663-8501, Japan
  • Study Site 3920029
    Nagoya, 466-8550, Japan
  • Study Site 3920064
    Okayama, 710-8602, Japan
  • Study Site 3920033
    Saitama, 339-8551, Japan
  • Study Site 3920025
    Tokyo, 160-0023, Japan
  • Study Site 4220007
    Beirut, 165191, Lebanon
  • Study Site 4580001
    Kuala Lumpur, 50400, Malaysia
  • Study Site 5280006
    Amsterdam Zuidoost, 1105 AZ, Netherlands
  • Study Site 5280008
    Nijmegen, 6500, Netherlands
  • Study Site 5280007
    Utrecht, 3584, Netherlands
  • Study Site 6080001
    Cebu City, 6000, Philippines
  • Study Site 6080002
    Davao City, 8000, Philippines
  • Study Site 6160013
    Gdansk, 80-952, Poland
  • Study Site 6160038
    Krakow, 31-531, Poland
  • Study Site 6160035
    Rzeszow, 35-301, Poland
  • Study Site 6160014
    Wroclaw, 50-367, Poland
  • Study Site 6200001
    Porto, 4200-319, Portugal
  • Study Site 6420030
    Bucharest, 011026, Romania
  • Study Site 6420037
    Timisoara, 300011, Romania
  • Study Site 7100001
    Parktown, 2193, South Africa
  • Study Site 7240008
    A Coruna, 15006, Spain
  • Study Site 7240021
    Barcelona, 08035, Spain
  • Study Site 7240007
    Madrid, 28046, Spain
  • Study Site 7240023
    Valencia, 46026, Spain
  • Study Site 7560010
    Luzern, 6000, Switzerland
  • Study Site 7640001
    Bangkok, 10330, Thailand
  • Study Site 7640005
    Bangkok, 10700, Thailand
  • Study Site 7640002
    Chiang Mai, 50200, Thailand
  • Study Site 7640004
    Khon Kaen, 40002, Thailand
  • Study Site 7640003
    Songkhla, 90110, Thailand
  • Study Site 8040007
    Dnipropetrovsk, 49102, Ukraine
  • Study Site 8040005
    Lviv, 79044, Ukraine
  • Study Site 8260008
    London, NW3 2QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jan 2021 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2021, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2014
First posted
Jun 24, 2014
Start
Oct 13, 2014
Primary completionActual
Jan 19, 2021
CompletionActual
Jan 19, 2021
Results first posted
Oct 27, 2021
Last update
Oct 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02172950
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Oct 13, 2014
Primary completion
Jan 19, 2021
Completion
Jan 19, 2021
Results posted
Oct 27, 2021
Last update
Oct 27, 2021

Study contacts

Program Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lonoctocog alfa

Start the discussion